Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · IEX Real-Time Price · USD
2.300
+0.010 (0.44%)
At close: Mar 27, 2024, 4:00 PM
2.340
+0.040 (1.74%)
Pre-market: Mar 28, 2024, 4:43 AM EDT

Inhibikase Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021202020192018
Market Capitalization
148133766--
Market Cap Growth
--37.83%-65.89%-44.21%---
Enterprise Value
2-5-10-4530-0
PE Ratio
-0.41-0.41-0.70-2.50-23.27--
PS Ratio
54.8630.10102.1811.9394.89--
PB Ratio
1.300.710.600.966.77--
P/FCF Ratio
-0.43-0.43-0.72-2.59-58.69--
P/OCF Ratio
-0.43-0.43-0.73-2.59-58.69--
EV/Sales Ratio
6.03-18.73-83.37-1.1475.370.32-0.04
EV/EBITDA Ratio
0.260.260.570.24-18.68-0.060.07
EV/EBIT Ratio
0.260.260.570.24-18.68-0.060.07
EV/FCF Ratio
0.270.270.580.25-46.61-1.05-0.20
Debt / Equity Ratio
0.050.050.010.010.03-0.08-0.30
Debt / EBITDA Ratio
-0.03-0.03-0.01-0.02-0.11-0.07-0.11
Debt / FCF Ratio
-0.03-0.03-0.01-0.02-0.28-1.100.33
Quick Ratio
3.853.856.2510.082.960.000.24
Current Ratio
4.134.136.6010.483.130.010.35
Asset Turnover
0.010.010.000.080.090.78-
Interest Coverage
----741.16-95.86-229.44-69.96
Return on Equity (ROE)
-107.50%-107.50%-65.80%-43.30%-107.60%217.30%-
Return on Assets (ROA)
-91.80%-91.80%-57.40%-39.60%-38.40%-396.80%-
Return on Capital (ROIC)
-174.55%-174.55%-85.59%-38.19%-27.90%138.43%389.93%
Earnings Yield
-133.16%-242.67%-143.13%-39.99%-4.30%--
FCF Yield
-126.65%-230.82%-139.49%-38.66%-1.70%--
Buyback Yield / Dilution
-26.28%-26.28%-39.15%-121.72%-0.39%-2.08%-
Total Shareholder Return
-26.28%-26.28%-39.15%-121.72%-0.39%-2.08%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).